Literature DB >> 33420548

MicroRNA-1246 regulates proliferation, invasion, and differentiation in human vascular smooth muscle cells by targeting cystic fibrosis transmembrane conductance regulator (CFTR).

Diguang Pan1, Guiyong Liu2, Bin Li2, Jingbo Jiang2, Wei Chen2, Wei Li2, Lin Zhang2, Yubao Hu2, Shuyun Xie2, Huayun Yang2.   

Abstract

MicroRNA (miRNA) plays a key role in the proliferation and invasion of vascular smooth muscle cells (VSMCs). However, the role and underlying mechanism of miRNAs in VSMCs are not fully understood. Therefore, this study was designed to investigate the role and mechanism of microRNA-1246 (miR-1246) in VSMCs. VSMCs were cultured, and the proliferation of VSMCs was stimulated by platelet-derived growth factor (PDGF-BB) or 15% fetal bovine serum (FBS). The quantitative reverse transcription PCR (qRT-PCR) was used to detect the expression levels of miR-1246 and cystic fibrosis transmembrane conductance regulator (CFTR) in VSMCs. The CCK-8 assay and transwell assay were used to detect the proliferation and invasion of VSMCs. Target gene prediction and screening and luciferase reporter assays were used to verify downstream target genes of miR-1246. Western blotting was used to detect the protein expression levels of PCNA, α-SMA, SM-MHC, Collagen-1, and Cyclin D1 in VSMCs. PDGF-BB and FBS treatment induced VSMCs proliferation and the upregulation of miR-1246 expression. Overexpression of miR-1246 promoted VSMCs proliferation, invasion, and differentiation towards synthetic phenotype, while knockdown of miR-1246 had opposite effects. In addition, CFTR was found to be a direct target for miR-1246, and miR-1246 inhibited the expression of CFTR. Moreover, overexpression of CFTR inhibited VSMC proliferation and synthetic differentiation, while overexpression of miR-1246 partly abolished the effects of CFTR overexpression on VSMCs proliferation and differentiation. Our data suggest that MiR-1246 promotes VSMC proliferation, invasion, and differentiation to synthetic phenotype by regulating CFTR. MiR-1246 may be a potential therapeutic target for atherosclerosis.

Entities:  

Keywords:  CFTR; Differentiation; Invasion; Proliferation; VSMCs; miR-1246

Mesh:

Substances:

Year:  2021        PMID: 33420548     DOI: 10.1007/s00424-020-02498-8

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  30 in total

1.  Free Fatty Acids Induce Autophagy and LOX-1 Upregulation in Cultured Aortic Vascular Smooth Muscle Cells.

Authors:  Cheng-I Cheng; Yueh-Hong Lee; Po-Han Chen; Yu-Chun Lin; Ming-Huei Chou; Ying-Hsien Kao
Journal:  J Cell Biochem       Date:  2017-01-10       Impact factor: 4.429

Review 2.  Large animal models for vaccine development and testing.

Authors:  Volker Gerdts; Heather L Wilson; Francois Meurens; Sylvia van Drunen Littel-van den Hurk; Don Wilson; Stewart Walker; Colette Wheler; Hugh Townsend; Andrew A Potter
Journal:  ILAR J       Date:  2015

3.  Atherosclerosis linked to faulty DNA repair in VSMCs.

Authors:  Caroline Barranco
Journal:  Nat Rev Cardiol       Date:  2018-07       Impact factor: 32.419

Review 4.  Animal models of atherosclerosis.

Authors:  Besa Emini Veseli; Paola Perrotta; Gregory R A De Meyer; Lynn Roth; Carole Van der Donckt; Wim Martinet; Guido R Y De Meyer
Journal:  Eur J Pharmacol       Date:  2017-05-05       Impact factor: 4.432

5.  Artemisinin inhibits the proliferation, migration, and inflammatory reaction induced by tumor necrosis factor-α in vascular smooth muscle cells through nuclear factor kappa B pathway.

Authors:  Qian Cao; Yan Jiang; Jin Shi; Changlu Xu; Xiaoxia Liu; Tiangui Yang; Peng Fu; Tiesheng Niu
Journal:  J Surg Res       Date:  2014-12-11       Impact factor: 2.192

Review 6.  Targeting smooth muscle microRNAs for therapeutic benefit in vascular disease.

Authors:  Sebastian Albinsson; Karl Swärd
Journal:  Pharmacol Res       Date:  2013-04-21       Impact factor: 7.658

7.  Expression profile of long non-coding RNAs in rat models of OSA-induced cardiovascular disease: new insight into pathogenesis.

Authors:  Qingshi Chen; Guofu Lin; Jiefeng Huang; Gongping Chen; Xiaoyun Huang; Qichang Lin
Journal:  Sleep Breath       Date:  2018-12-07       Impact factor: 2.655

8.  Gene expression profiles and signaling mechanisms in α2B-adrenoceptor-evoked proliferation of vascular smooth muscle cells.

Authors:  Anna Huhtinen; Vesa Hongisto; Asta Laiho; Eliisa Löyttyniemi; Dirk Pijnenburg; Mika Scheinin
Journal:  BMC Syst Biol       Date:  2017-06-28

9.  Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation.

Authors:  Daniel Gelfond; Sonya Heltshe; Changxing Ma; Steven M Rowe; Carla Frederick; Ahmet Uluer; Leonard Sicilian; Michael Konstan; Elizabeth Tullis; R N Christine Roach; Katherine Griffin; Elizabeth Joseloff; Drucy Borowitz
Journal:  Clin Transl Gastroenterol       Date:  2017-03-16       Impact factor: 4.488

Review 10.  Regulation of microRNA function in animals.

Authors:  Luca F R Gebert; Ian J MacRae
Journal:  Nat Rev Mol Cell Biol       Date:  2019-01       Impact factor: 94.444

View more
  3 in total

1.  Dehydroepiandrosterone inhibits vascular proliferation and inflammation by modulating the miR-486a-3p/NLRP3 axis.

Authors:  Manli Zhang; Manna Zhang; Wenli Wang; Hui Chen; Xia Wang; Kun Zhao; Ze Li; Jiangqing Xu; Fei Tong
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  CFTR Suppresses Neointimal Formation Through Attenuating Proliferation and Migration of Aortic Smooth Muscle Cells.

Authors:  Liu-Yi Lu; Ni Pan; Ze-Han Huang; Jing-Song Wang; Yong-Bo Tang; Hong-Shuo Sun; Hui Han; Han-Yan Yang; Jun-Zhen Zhu; Yong-Yuan Guan; Bin Zhang; Dong-Zhi Li; Guan-Lei Wang
Journal:  J Cardiovasc Pharmacol       Date:  2022-06-01       Impact factor: 3.271

3.  Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma.

Authors:  José A Cañas; Marcela Valverde-Monge; José M Rodrigo-Muñoz; Beatriz Sastre; Marta Gil-Martínez; Raquel García-Latorre; Manuel J Rial; Aida Gómez-Cardeñosa; Mar Fernández-Nieto; Erwin J Pinillos-Robles; María J Rodríguez-Nieto; Nicolás González-Mangado; Joaquín Sastre; Victoria Del Pozo
Journal:  J Pers Med       Date:  2021-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.